Published in Lab Law Weekly, April 28th, 2006
Recently EKF was informed of HemoCue's decision to enforce the District Court's decision regarding a patent involved in multiple processes, both in Germany and in the United States. This means that EKF no longer can manufacture, or sell, the infringing product.
Said Clas Runnberg, HemoCue's director of corporate affairs, "In our opinion, the decision, and the reasoning upon which it is based, is entirely in HemoCue's favor. This made it very easy for us to determine that we wanted the first instance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly